Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Safety and Dose-finding Study of Autologous Muscle-specific Tyrosine Kinase Chimeric Autoantibody Receptor T Cells (MuSK-CAART) in Subjects With Anti-MuSK-antibody-positive Myasthenia Gravis

X
Trial Profile

A Phase 1, Open-label, Safety and Dose-finding Study of Autologous Muscle-specific Tyrosine Kinase Chimeric Autoantibody Receptor T Cells (MuSK-CAART) in Subjects With Anti-MuSK-antibody-positive Myasthenia Gravis

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MuSK-CAART (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions; First in man
  • Acronyms MusCAARTes
  • Sponsors Cabaletta Bio
  • Most Recent Events

    • 15 May 2024 According to a Cabaletta Bio media release, trial is currently not dosing patients as clinical and translational data from the A1 and A2 cohorts is being evaluated.
    • 10 Aug 2023 According to a Cabaletta Bio media release, based on emerging data from the DesCAARTes study, clinical trial timelines are under evaluation for this Phase 1, open-label MusCAARTes study.
    • 16 Mar 2023 According to a Cabaletta Bio media release, trial design published in Nature Biotechnology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top